Literature DB >> 1500200

Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults.

S J Cryz1, M M Levine, G Losonsky, J B Kaper, B Althaus.   

Abstract

Adult volunteers received a booster dose (4 x 10(8) CFU) of attenuated Vibrio cholerae CVD 103-HgR oral vaccine 15 or 24 months after primary immunization. The immune response was modest, presumably due to rapid clearance of the vaccine strain by a primed immune system.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1500200      PMCID： PMC257409          DOI： 10.1128/iai.60.9.3916-3917.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  6 in total

1.  Recombinant attenuated Vibrio cholerae strains used as live oral vaccines.

Authors:  J B Kaper; M M Levine
Journal:  Res Microbiol       Date:  1990 Sep-Oct       Impact factor: 3.992

2.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

3.  Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults.

Authors:  S J Cryz; M M Levine; J B Kaper; E Fürer; B Althaus
Journal:  Vaccine       Date:  1990-12       Impact factor: 3.641

4.  Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.

Authors:  S Migasena; P Pitisuttitham; B Prayurahong; P Suntharasamai; W Supanaranond; V Desakorn; U Vongsthongsri; B Tall; J Ketley; G Losonsky
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

5.  Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.

Authors:  A S Benenson; A Saad; W H Mosley
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

6.  Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology.

Authors:  M M Levine; C R Young; R E Black; Y Takeda; R A Finkelstein
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948
  6 in total
  8 in total

1.  Immunogenicity in Peruvian volunteers of a booster dose of oral cholera vaccine consisting of whole cells plus recombinant B subunit.

Authors:  R E Begue; G Castellares; C Cabezas; J L Sanchez; R Meza; D M Watts; D N Taylor
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

2.  Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.

Authors:  H Kollaritsch; E Furer; C Herzog; G Wiedermann; J U Que; S J Cryz
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

3.  Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.

Authors:  E Gotuzzo; B Butron; C Seas; M Penny; R Ruiz; G Losonsky; C F Lanata; S S Wasserman; E Salazar; J B Kaper
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

4.  Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria.

Authors:  J F Viret; D Favre; B Wegmüller; C Herzog; J U Que; S J Cryz; A B Lang
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

5.  Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.

Authors:  S J Cryz; J U Que; M M Levine; G Wiedermann; H Kollaritsch
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

6.  Use of stabilized luciferase-expressing plasmids to examine in vivo-induced promoters in the Vibrio cholerae vaccine strain CVD 103-HgR.

Authors:  Cara E Morin; James B Kaper
Journal:  FEMS Immunol Med Microbiol       Date:  2009-07-01

7.  Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022.

Authors:  Jennifer P Collins; Edward T Ryan; Karen K Wong; Matthew F Daley; Adam J Ratner; Grace D Appiah; Pablo J Sanchez; Bruce J Gutelius
Journal:  MMWR Recomm Rep       Date:  2022-09-30

Review 8.  Acute, infectious diarrhea among children in developing countries.

Authors:  Laura Jean Podewils; Eric D Mintz; James P Nataro; Umesh D Parashar
Journal:  Semin Pediatr Infect Dis       Date:  2004-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.